Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | YES1 | P07947 | 1/20 | 0.43 |
| ▸ | FGR | P09769 | 1/20 | 0.43 |
| ▸ | TEC | P42680 | 1/20 | 0.43 |
| ▸ | BMX | P51813 | 1/20 | 0.43 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1727066 | 0.89 | BTK (0.65) | BTKKCNH2 | |
| SCHEMBL13178761 | 0.80 | BTK (0.60) | BTKKCNH2YES1FGRTEC | |
| SCHEMBL13178757 | 0.80 | BTK (0.56) | BTKKCNH2YES1FGRTEC | |
| SCHEMBL13178740 | 0.80 | BTK (0.55) | BTKKCNH2YES1FGRTEC | |
| SCHEMBL13178742 | 0.80 | BTK (0.61) | BTKKCNH2YES1FGRTEC | |
| SCHEMBL13178745 | 0.80 | BTK (0.66) | BTKKCNH2YES1FGRTEC | |
| SCHEMBL13178721 | 0.79 | BTK (0.66) | BTKKCNH2YES1FGRTEC | |
| SCHEMBL13178683 | 0.79 | BTK (0.65) | BTKKCNH2YES1FGRTEC | |
| SCHEMBL3051457 | 0.79 | BTK (0.68) | BTKKCNH2 | |
| SCHEMBL1725644 | 0.78 | BTK (0.54) | BTKKCNH2YES1FGRTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299077-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | BTK 1/4885KCNH2 2156/4885YES1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.